The FDA approved biosimilars from Organon on September 2, 2025.
2 reports, 2 independent
Updated Sep 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved biosimilars from Organon on September 2, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA guidance changes affect biosimilar approval, impacting Coherus Oncology, Inc.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- Vesselon seeks regulatory approval from the FDA for its new drug delivery systems.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
Coverage
Newest first; wire copies grouped- PR NewswireUS Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively S
- Insider MonkeyOrganon & Co. (OGN) Advances VTAMA Cream, Strengthens Women’s Health Portfolio We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Organon & Co. is placed fourth among th